

Reconsideration of the application and the finality of the Office Action in view of the following Amendments and Remarks is respectfully requested.

AMENDMENTS

Please amend the claims as follows:

C1
18. (Amended) A pharmaceutical composition comprising an effective amount of an antibody according to claim 11.

C2
26. (Amended) The diagnostic kit of claim 9, wherein the biological sample is obtained from an individual treated with [monoclonal antibody 1A7] an antibody according to claim 1.

REMARKS

Regarding the formalities:

Applicants will cancel claims 5 and 6 upon notification of allowability of the claims under consideration. Applicants reserve the right to pursue claims to methods of treatment, including the subject matter of claims 5 and 6, in a divisional or continuation application, if and when these claims are canceled.

Applicants gratefully acknowledge withdrawal of various 35 USC § 112 rejections in light of amendments and arguments previously made.

Applicants note with concern the finality of the action in Paper 11, and request that the finality of the action be withdrawn according to the procedure in MPEP § 706.07(d).